[Home ] [Archive]    
:: Main :: About :: Current Issue :: Archive :: Search :: Contact ::
:: Volume 13, Issue 1 (6-2019) ::
Iran J Virol 2019, 13(1): 16-23 Back to browse issues page
The Indinavir Derivate as a Novel Pharmacophore for Treatment of HTLV-1 Viral Infections
Masoud Youssefi , Kiarash Ghazvini, Carlos Brites , Mohsen Karbalaei , Masoud Keikha *
Abstract:   (1363 Views)
Background and Aims: Human T-lymphotropic virus type 1 (HTLV-1), is as a type C retrovirus, which was first isolated from a patient with Adult T-cell leukemia/lymphoma (ATLL). Approximately 10-20 million people are infected by HTLV-1 virus worldwide, but only 5-10% of them develop clinical manifestations such as Acute-T lymphoma (ATL), HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), uveitis, and infective dermatitis. Indinavir was the first protease inhibitor used for treating HIV-1. It has some activity on HTLV-1, but it is not fully able to inhibit the HTLV-1 protease. Nowadays, design and construction of novel pharmacophore compounds can serve as an appropriate replacement for Indinavir. 
Materials and Methods: In the present research, we used bioinformatics studies, to evaluate the potential role of four novel pharmacophres with inhibitory function on HTLV-1 protease, so called KMI pharmacophores (Keikha Modified Indinavir).
Results: After a detailed structural analysis of each of them, it seems all four designed phamacophores, (especially KMI-3) could be more effective on HTLV-1 protease than Indinavir.
Conclusions: According to exact in silico evaluations of each four pharmacophores, KMI-3 demonstrated a potential for its use on treatment of HTLV-1 infections. 
Keywords: HTLV-1, Protease, Indinavir, Molecular docking
Full-Text [PDF 952 kb]   (1058 Downloads)    
Type of Study: Original article | Subject: General
Received: 2019/10/31 | Accepted: 2020/03/31 | Published: 2020/03/31
Send email to the article author

Add your comments about this article
Your username or Email:


XML     Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

youssefi M, ghazvini K, Brites C, Karbalaei M, keikha M. The Indinavir Derivate as a Novel Pharmacophore for Treatment of HTLV-1 Viral Infections. Iran J Virol. 2019; 13 (1) :16-23
URL: http://journal.isv.org.ir/article-1-366-en.html

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 13, Issue 1 (6-2019) Back to browse issues page
Persian site map - English site map - Created in 0.04 seconds with 30 queries by YEKTAWEB 4463